Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sarepta Therapeutics (NQ: SRPT ) 113.33 -10.13 (-8.21%) Streaming Delayed Price Updated: 4:00 PM EDT, May 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sarepta Therapeutics < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals? January 25, 2024 It's always tough to be compared to a giant. Via The Motley Fool Sarepta Therapeutics Inc.: Why it's a rising gene therapy star January 23, 2024 Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases. Via MarketBeat Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today January 22, 2024 One pundit feels there is solid potential in one of the company's more recently approved drugs. Via The Motley Fool Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market January 16, 2024 In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for. Via InvestorPlace Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 January 16, 2024 From Sarepta Therapeutics, Inc. Via Business Wire A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics January 10, 2024 Via Benzinga Sarepta Therapeutics Inc. (NASDAQ: SRPT) Making Surprising Moves in Tuesday Session January 09, 2024 Via Investor Brand Network Stocks Flip To Losses, Nvidia Defies Gravity, Bitcoin Pauses For A Breather: What's Driving Markets Tuesday? January 09, 2024 Tuesday on Wall Street was marked by a subdued trend in major equity indices as investors remained cautious ahead of key inflation data scheduled for release on Thursday and the kick-off of the... Via Benzinga Topics Economy Exposures Interest Rates Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year January 09, 2024 Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product Via Benzinga Bumble (BMBL) Stock Pops as Elliott Builds a Stake in Rival Match January 09, 2024 Bumble stock is rising on Tuesday as BMBL investors learn of a $1 billion investment in rival dating services company Match. Via InvestorPlace Why Is Sarepta Therapeutics (SRPT) Stock Up Today? January 09, 2024 Sarepta Therapeutics stock is rising higher on Tuesday as SRPT investors react to positive comments from company CEO Douglas Ingram. Via InvestorPlace The Latest Analyst Ratings for Sarepta Therapeutics December 12, 2023 Via Benzinga Could Sarepta Therapeutics Stock Help You Become a Millionaire? December 09, 2023 Can this struggling stock turn its fortunes around? Via The Motley Fool Analyst Ratings for Sarepta Therapeutics November 21, 2023 Via Benzinga Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday January 09, 2024 U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday. Via Benzinga Topics Stocks Exposures US Equities 2 Growth Stocks That Could Make You Richer in 2024 and Beyond January 09, 2024 Last year wasn't great for either stock, but that's no reason to ignore them. Via The Motley Fool Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue January 08, 2024 From Sarepta Therapeutics, Inc. Via Business Wire 5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday January 08, 2024 The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. Via Benzinga 3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024 January 07, 2024 Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech... Via Talk Markets Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 January 04, 2024 Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction... Via Benzinga Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Sarepta Therapeutics, Inc. Via Business Wire Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 29, 2023 From Sarepta Therapeutics, Inc. Via Business Wire 3 Things About Sarepta Therapeutics Every Smart Investor Knows December 28, 2023 Mastering this stock requires appreciating a few scientific nuances. Via The Motley Fool 10 Health Care Stocks Whale Activity In Today's Session December 27, 2023 Via Benzinga Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock? December 22, 2023 Both develop medicines for rare diseases, and each aims to conquer a niche market. Via The Motley Fool Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status December 22, 2023 From Sarepta Therapeutics, Inc. Via Business Wire 1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond December 17, 2023 Many investors are bailing out, but that might be a mistake. Via The Motley Fool My Take: 4 Strong Growth Stocks to Buy This Week December 08, 2023 These strong stocks are still available at a great price. That may not be the case a whole lot longer. Via The Motley Fool Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 30, 2023 From Sarepta Therapeutics, Inc. Via Business Wire ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT November 18, 2023 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.